Information Society Services


About Maxicells

About Maxicells

In accordance with the government's goal of localization in health and medicine; Maxicells initiated its investments in 2017, aiming to become the leading biological drug provider and manufacturer both in Turkey and throughout the world. Maxicells has set out to produce specific blood products that have already been manufactured by a few centers in the world, however not yet been produced in Turkey. Maxicells, which has already prepared its investment plans to build the very first plant of Turkey to produce specific blood products, has undertaken the procurement of  4 main plasma products (factor 8, factor 9, immunoglobulin and albumin) as finished products within the 5-year period until the beginning of domestic production.

Do You Have Any Questions?

You can request further information about our products by contacting our team members. You may also submit us additional information by filling out our Adverse Effect Reporting Form.

Contact Form